CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 23 enrolled
Drug / intervention
Fluticasone Propionate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05444543
NCT05444543Phase 4Completed
CompareCT.gov

Effectiveness of Cycling of Topical Steroid Therapy in Maintaining Clinical and Histologic Remission in Eosinophilic Esophagitis

University Hospitals Cleveland Medical Center·interventional·Posted Jul 6, 2022·Updated Nov 7, 2024

In Brief

A Phase 4 clinical trial evaluating Fluticasone Propionate and Budesonide for Eosinophilic Esophagitis. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The purpose of our research study is to assess whether patients with EoE who have achieved control of their disease on topical Fluticasone or Budesonide are able to cycle or take breaks from their treatment with continued remission of their EoE. There will be 30 participants enrolled in this study. There will be 15 patients who will stay on steroid therapy every day and 15 patients who will cycle their steroid therapy on and off to help us compare the two groups. The cycling group will cycle their steroid therapy in a three-months on three-months off fashion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedJul 6, 2022
Enrollment StartNov 17, 2021
Primary CompletionOct 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.0 years ago

Interventions

Fluticasone Propionatedrug

Participants will cycle topical steroid in a three-months on three-months off fashion

Budesonidedrug

Participants will cycle topical steroid in a three-months on three-months off fashion